Apalutamide radio-sensitisation of prostate cancer.
Christos KakouratosDimitra KalamidaIoannis LamprouErasmia XanthopoulouChristos NanosAlexandra GiatromanolakiMichael I KoukourakisPublished in: British journal of cancer (2021)
In vitro and in vivo experiments support the superiority of apalutamide over bicalutamide in combination with radiotherapy in prostate cancer. Clinical studies are encouraged to show whether replacement of bicalutamide with apalutamide may improve the curability rates.